Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 6/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.44 |
| ▸ | POLA1 | P09884 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.33 |
| ▸ | ALB | P02768 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.33 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.33 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.33 |
| ▸ | POLG | P54098 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.33 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20221805 | 0.92 | STING1 (0.46) | STING1PDE3APDE4DSLC29A1POLA1 | |
| SCHEMBL16480807 | 0.91 | STING1 (0.47) | STING1PDE3APDE4DSLC29A1POLA1 | |
| SCHEMBL16480783 | 0.91 | STING1 (0.47) | STING1PDE3APDE4DSLC29A1POLA1 | |
| SCHEMBL16480599 | 0.91 | STING1 (0.47) | STING1PDE3APDE4DSLC29A1POLA1 | |
| SCHEMBL20213192 | 0.87 | PDE3A (0.47) | STING1PDE3APDE4DSLC29A1POLA1 | |
| SCHEMBL20709855 | 0.86 | STING1 (0.46) | STING1PDE3APDE4DSLC29A1POLA1 | |
| SCHEMBL22958870 | 0.86 | STING1 (0.46) | STING1PDE3APDE4DSLC29A1POLA1 | |
| SCHEMBL20213212 | 0.84 | PDE3A (0.44) | STING1PDE3APDE4DSLC29A1POLA1 | |
| SCHEMBL20213095 | 0.84 | PDE3A (0.44) | STING1PDE3APDE4DSLC29A1POLA1 | |
| SCHEMBL18263750 | 0.84 | PDE3A (0.44) | STING1PDE3APDE4DSLC29A1POLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3303359-B1 | NUCLEOTIDES FOR THE TREATMENT OF CANCER | IDENIX PHARMACEUTICALS LLC (US) | 2024-11-06 | — | — | EP | disclosed |
| US-10766917-B2 | Nucleotides for the treatment of cancer | IDENIX PHARMACEUTICALS LLC (US) | 2020-09-08 | — | — | US | disclosed |
| US-10766917-B2 | Nucleotides for the treatment of cancer | IDENIX PHARMACEUTICALS LLC (US) | 2020-09-08 | — | — | US | disclosed |
| US-20190192548-A1 | USE OF CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVESFOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2019-06-27 | — | — | US | disclosed |
| US-20180155385-A1 | NUCLEOTIDES FOR THE TREATMENT OF CANCER | IDENIX PHARMACEUTICALS LLC (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180155385-A1 | NUCLEOTIDES FOR THE TREATMENT OF CANCER | IDENIX PHARMACEUTICALS LLC (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180155385-A1 | NUCLEOTIDES FOR THE TREATMENT OF CANCER | IDENIX PHARMACEUTICALS LLC (US) | 2018-06-07 | — | — | US | disclosed |
| EP-3303359-A1 | NUCLEOTIDES FOR THE TREATMENT OF CANCER | Idenix Pharmaceuticals LLC (US) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016188943-A1 | NUCLEOTIDES FOR THE TREATMENT OF CANCER | IDENIX PHARMACEUTICALS LLC (US) | 2016-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155385-A1 | NUCLEOTIDES FOR THE TREATMENT OF CANCER | NUDT1, NTPCR, ENTPD5 | STING1 516/4885PDE3A 698/4885PDE4D 278/4885 |
| US-20190192548-A1 | USE OF CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVESFOR THE TREATMENT OF VIRAL DISEASES | PNP, ENTPD5, TYMP | STING1 187/4885PDE3A 240/4885PDE4D 248/4885 |
| US-10766917-B2 | Nucleotides for the treatment of cancer | NUDT1, NTPCR, ENTPD5 | STING1 516/4885PDE3A 698/4885PDE4D 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.